메인 페이지
- Leading the Future of Healthcare
through R&D Innovation and a Global Value Chain - ATGC currently has two products nearing commercialization through its own research and development capabilities and is planning to expand indications and therapeutic areas.
-
ATGC'sLab
- ATGC currently has two products nearing commercialization through its own research and development capabilities and is planning to expand indications and therapeutic areas.
Our
Pipeline
-
Botulinum
toxin
type
A complex
(900KDa)
and
non-toxin
botulinum
pure
toxin
type A
(150KDa)
as the main
ingredients
for the
treatment
of frown lines,
a biosimilar
product
with our
process
development
technology.
-
A liquid
combination
of botulinum
toxin
and
hyaluronic
acid,
a biobetter
aimed at
chondroprotection
and pain
relief for
osteoarthritis.
-
Recombinant
protein
fusing
a GLP-1
analog
with a
platform
hybrid
IgG,
a novel
therapeutic
with
increased
long-acting
activity
and
efficacy
of GLP-1
for the
treatment
of type 2
diabetes.
Our Strategy
ATGC has adopted an open innovation strategy that
promotes business through strategic partnerships
based on its core competency of R&D technology.
-
-
We have adopted an open innovation strategy by partnering with production experts to efficiently spread and distribute medicines resulting from R&D activities.
-
We work with trusted partners to develop and distribute medicines. We work together to plan and execute the marketing and sales of medicines.
